In vitro susceptibility of Candida spp. isolated from clinical specimens against some antifungal agents

Kan kültürlerinden izole edilen Candida türlerine karşı ketokonazol (KET), flukonazol (FLU),, itra-konazol (ITRA), amfoterisin B (AmpB) ve flusitozin (FCU) 'in in vitro duyarlılıkları vorikonazol (VOR) ile karşılaştırılarak değerlendirilmiştir. En sık identifıye edilen Candida, türleri sırasıyla C. albicans (71), C. parapsilosis (16), C. glabrata (12), C tropicalis (9), C. kefyr (8) ve birer adet C. lustaniae, C. spherical, Ç. sake ve C. lambria 'dır. KET, FLU, ITRA, Amp B, FCU ve VOR'un in vitro aktivitelerinin değerlendirilmesinde NCCLS M 27-A metodu kullanılmıştır. MİK değerleri RPMI 1640 besiyeri kullanılarak mikrodilüsyon yöntemi ile değer­lendirilmiştir. Test edilen Candida türleri; KET, ITRA, FCU, AmpB ve VOR 'a dirençli değildir. Sadece iki C albi­cans izolatı FLU(MIC;$\geq 32 \mu g/ml$ ) 'e dirençlidir. Suşların; KET ve FLU için %17.5, ITRA için %8.3'ünde orta duyarlılık görülmüştür. 120 Candida izolatı KET (MİK;$\leq 8 \mu g/ml$ ), VOR (MİK;$\leq 0.03 \mu g/m$ ); ITRA (MİK;

Klinik örneklerden izole edilen Candida türlerine karşı bazı antifungal ajanların duyarlılıklarının araştırılması

We evaluated the in vitro activity of ketoconazole (KET), fluconazole (FLU), itraconazole (ITRA), amphotericin B (AmpB), flucytosine (FCU) in comparison to voriconazole (VOR) against Candida spe­cies isolated from blood cultures. The most common species of identified Candida were C. albicans (71), followed by C parapsilosis (16), C. glabrata (12) C. tropicalis (9), C. kefyr (8) and one of C. lustaniae, C. spherical, C. sake, C. lambria respectively. NCCLS M 27-A method was used to evaluate the activity of KET, FLU, ITRA, AmpB, FCU and VOR. The MICs of the strains were evaluated by RPMI 1640 medium with microdilution method. There were no isolates of tested Candida spp. resistant to KET, ITRA, FCU, AmpB and VOR. Only two ofC. albicans isolates were resistant to FLU (MIC; >32jug/ml). Intermediate resistant appeared in 17.5% isolates to KET and FLU, 8.3% isolates to ITRA. Among 120 Candida isolates were found high­ly susceptible to KET (MIC;<8 ug/ml) followed by VOR (MIC;<0.03jug/ml), ITRA (MIC;<0.125 ug/ml) FCU (MIC;<4 ug/ml) AmpB (MIC; ug/ml), and FLU (MIC; <8 ug/ml) so FCU, AmpB and VOR were each more active than KET, FLU, and ITRA.

___

Yang, Y.L., Ho, Y.A., Cheng, H.H., Ho, M., Lo, H. J., "Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis". Inf. Cont. Hosp. Epidem., 25: 60-64, 2004.

Rex, J.H., Walsh, T. J., Sobel, J.D., Filler, S.G., Pappas, P.G., Dismukes, W.E.,Edwards, J.E., "Practice guidelines for the treatment of Candidiasis". Clin. Infect. Dis., 30: 662-678, 2000.

National Committee for Clinical Laboratory Standards: method for broth dilution antifungal susceptibility testing yeast; approved standard. M27-A, NCCLS, VA Medical Center, 1996; 15, Tuscon.

Özçelik, B., Çıtak, S., Cesur, S., Abbasoğlu, U., içli, E, "In vitro Susceptibility of Candida spp to Antifungal Agents". Drug. Met & Drug Inter., 20, 1-2, 5-8, 2004.

Letscher-Bru, V., Herbrecht, R., "Caspofungin: the first representative of a new antifungal class". J. Antimic. Chemother, 51: 513-521, 2003.

Arora, D., Nguyen, M.H., Clandy, C.J., "Effect of concentrations exceeding minimum inhibitory concentrations of caspofungin on the selection of resistant strains of Candida spp".J. Undergrad. Res., 7: 1-7, 2005.

Kovacicova, G., Mateicka, E, Haznen, J., "Breakthrough candidemias during empirical therapy with fluconazole in non-cancer and non-HIV adults caused by in vitro susceptible Candida spp. Report of 33 cases". Scand. J. Infect. Dis., 33: 749-751, 2001.

Girmenia, C, Tuccinardi, C, Santilli, S., "In vitro activity of fluconazole and voriconazole against isolates of Candida albicans from patients with haematological malignancies". J. Antimic. Chemother. 46: 479-483, 2000.

Pfaller, M.A., Diekema, D.J., Messer, S.A., Hollis, R.J., Jones, R.N., ""In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates". Antimicrob. Agents Chemother., 47: 1068-1071, 2003.

Evans, E.G.V., "The Challenge of Fungal Infections in the Critically 111". GileadScl, 13-28, 2002.

Guyen, M.H., "Influence of incubation time, inoculum size, and glucose concentration on spectrophotometric endpoint determination for amphotericin B, fluconazole and itraconazole". J. Clin. Microbiol, 37: 141-145, 1999.

Ruhnke, M., Eigler, A., Tennagen, I., "Emergence of fluconazole resistant isolates of Candida albicans in patients with recurrent oropharyngeal candidiasis and human immunodeficiency virus infection". J. Clin. Microbiol, 32: 2092-2098, 1994.

Kremery, V., Barnes, A.J., "Non-albicans Candida spp. causing fungemia: pathogenicity and antifungal resistance". J. Hosp. Infect, 50: 243-260, 2002.

Çıtak, S., Özçelik, B., Cesur, S., Abbasoğlu, IL, "In vitro susceptibility of Candida species isolated from blood culture againts some antifungal agents". Jpn. J. Infec. Dis., 58, 1, 44-6, 2005.

___